share_log

DEFA14A: Others

DEFA14A: Others

DEFA14A:其他
美股SEC公告 ·  11/01 17:12

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc. has filed Supplement No. 1 to the definitive proxy statement for its 2024 virtual annual meeting of stockholders with the U.S. Securities and Exchange Commission. This filing, dated October 28, 2024, includes amendments to correct scrivener's errors in two paragraphs related to corporate governance and director independence. The company's board has affirmed that all directors, except for three named individuals, meet the independence criteria set by Nasdaq listing standards. Currently, the board has an equal number of independent and non-independent members due to a recent resignation. The board is actively seeking to appoint an additional independent director by December 18, 2024, to comply with Nasdaq's requirement for the Audit Committee composition. The proxy materials for the annual meeting are available online for stockholders.
Conduit Pharmaceuticals Inc. has filed Supplement No. 1 to the definitive proxy statement for its 2024 virtual annual meeting of stockholders with the U.S. Securities and Exchange Commission. This filing, dated October 28, 2024, includes amendments to correct scrivener's errors in two paragraphs related to corporate governance and director independence. The company's board has affirmed that all directors, except for three named individuals, meet the independence criteria set by Nasdaq listing standards. Currently, the board has an equal number of independent and non-independent members due to a recent resignation. The board is actively seeking to appoint an additional independent director by December 18, 2024, to comply with Nasdaq's requirement for the Audit Committee composition. The proxy materials for the annual meeting are available online for stockholders.
Conduit Pharmaceuticals Inc.已經向美國證券交易委員會提交了關於其2024年虛擬股東年會的補充文件1。這一文件的日期爲2024年10月28日,其中修正了兩個涉及公司治理和董事獨立性的段落中正確書寫錯誤的修訂內容。公司董事會確認,除了三名具名個人外,所有董事都符合納斯達克上市標準規定的獨立標準。目前,由於最近一位成員的辭職,董事會的獨立和非獨立成員人數平等。董事會正在積極尋找在2024年12月18日之前任命一名額外的獨立董事,以便符合納斯達克對審計委員會組成的要求。股東可以在線獲取年會的代理材料。
Conduit Pharmaceuticals Inc.已經向美國證券交易委員會提交了關於其2024年虛擬股東年會的補充文件1。這一文件的日期爲2024年10月28日,其中修正了兩個涉及公司治理和董事獨立性的段落中正確書寫錯誤的修訂內容。公司董事會確認,除了三名具名個人外,所有董事都符合納斯達克上市標準規定的獨立標準。目前,由於最近一位成員的辭職,董事會的獨立和非獨立成員人數平等。董事會正在積極尋找在2024年12月18日之前任命一名額外的獨立董事,以便符合納斯達克對審計委員會組成的要求。股東可以在線獲取年會的代理材料。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息